# First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients

> **NCT02612051** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** GSK3008348 Nebuliser solution
- **DRUG:** Placebo Nebuliser solution
- **RADIATION:** GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion

## Key facts

- **NCT ID:** NCT02612051
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-04
- **Primary completion:** 2016-06-02
- **Final completion:** 2016-06-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612051, "First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02612051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*